These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 31394493)

  • 41. Evaluation of clinical outcome in children and adolescents receiving vancomycin for invasive infections due to methicillin-resistant Staphylococcus aureus: impact of increasing vancomycin MICs.
    Arun A; Swamy S; Jacob K; Sharma R; Kohlhoff SA; Hammerschlag MR
    Minerva Pediatr; 2018 Jun; 70(3):207-211. PubMed ID: 28006894
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Prospectively validated dosing nomograms for maximizing the pharmacodynamics of vancomycin administered by continuous infusion in critically ill patients.
    Pea F; Furlanut M; Negri C; Pavan F; Crapis M; Cristini F; Viale P
    Antimicrob Agents Chemother; 2009 May; 53(5):1863-7. PubMed ID: 19223642
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Optimal dose of vancomycin for treating methicillin-resistant Staphylococcus aureus pneumonia in critically ill patients.
    Chung J; Oh JM; Cho EM; Jang HJ; Hong SB; Lim CM; Koh YS
    Anaesth Intensive Care; 2011 Nov; 39(6):1030-7. PubMed ID: 22165354
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Population Pharmacokinetic Study of the Suitability of Standard Dosing Regimens of Amikacin in Critically Ill Patients with Open-Abdomen and Negative-Pressure Wound Therapy.
    Carrié C; Delzor F; Roure S; Dubuisson V; Petit L; Molimard M; Breilh D; Biais M
    Antimicrob Agents Chemother; 2020 Mar; 64(4):. PubMed ID: 31964795
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Optimizing Antimicrobial Dosing for Critically Ill Patients with MRSA Infections: A New Paradigm for Improving Efficacy during Continuous Renal Replacement Therapy.
    Chen J; Li S; Wang Q; Wang C; Qiu Y; Yang L; Han R; Du Q; Chen L; Dong Y; Wang T
    Pharmaceutics; 2022 Apr; 14(4):. PubMed ID: 35456676
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Establishment of an AUC
    Chavada R; Ghosh N; Sandaradura I; Maley M; Van Hal SJ
    Antimicrob Agents Chemother; 2017 May; 61(5):. PubMed ID: 28242672
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Doripenem dosing regimens in Asian critically ill patients with continuous renal replacement therapy.
    Chaijamorn W; Puchsaka P; Pattharachayakul S; Charoensareerat T; Srisawat N; Boonpeng A; Pummangura C
    J Crit Care; 2019 Aug; 52():233-236. PubMed ID: 31108327
    [No Abstract]   [Full Text] [Related]  

  • 48. Developments in the pharmacokinetic/pharmacodynamic index of linezolid: a step toward dose optimization using Monte Carlo simulation in critically ill patients.
    Dong H; Xie J; Chen L; Wang T; Sun J; Zhao Y; Dong Y
    Int J Infect Dis; 2014 May; 22():35-40. PubMed ID: 24603161
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Area under the concentration-time curve to minimum inhibitory concentration ratio as a predictor of vancomycin treatment outcome in methicillin-resistant Staphylococcus aureus bacteraemia.
    Jung Y; Song KH; Cho Je; Kim HS; Kim NH; Kim TS; Choe PG; Chung JY; Park WB; Bang JH; Kim ES; Park KU; Park SW; Kim HB; Kim NJ; Oh MD
    Int J Antimicrob Agents; 2014 Feb; 43(2):179-83. PubMed ID: 24315788
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Vancomycin population pharmacokinetics and dosing recommendations in haematologic malignancy with augmented renal clearance children.
    Lv CL; Lu JJ; Chen M; Zhang R; Li QC; Chen YY; Liu TT
    J Clin Pharm Ther; 2020 Dec; 45(6):1278-1287. PubMed ID: 32557716
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Vancomycin dosage optimization in patients with malignant haematological disease by pharmacokinetic/pharmacodynamic analysis.
    Fernández de Gatta Mdel M; Santos Buelga D; Sánchez Navarro A; Dominguez-Gil A; García MJ
    Clin Pharmacokinet; 2009; 48(4):273-80. PubMed ID: 19492872
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Evaluation of pharmacodynamic target attainment with vancomycin treatment of bacteremia due to Staphylococcus aureus methicillin resistant].
    Lepe JA; Gil-Navarro MV; Santos-Rubio MD; Bautista J; Aznar J
    Rev Esp Quimioter; 2010 Mar; 23(1):43-7. PubMed ID: 20232023
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Vancomycin Dosing Regimen by Monte Carlo Simulation in Patients on Intermittent High-Efficiency Hemodialysis (HEHD).
    Rungprai D; Jaruratanasirikul S; Wongpoowarak W; Pattharachayakul S; Wanakamanee U; Dandecha P; Jitsurong A
    J Med Assoc Thai; 2015 Jun; 98(6):606-15. PubMed ID: 26219166
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Pharmacokinetics of linezolid in critically ill patients on continuous renal replacement therapy: Influence of residual renal function on PK/PD target attainment.
    Barrasa H; Soraluce A; Isla A; Martín A; Maynar J; Canut A; Sánchez-Izquierdo JA; Rodríguez-Gascón A
    J Crit Care; 2019 Apr; 50():69-76. PubMed ID: 30496913
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Development of a vancomycin dosing approach for critically ill patients receiving hybrid hemodialysis using Monte Carlo simulation.
    Lewis SJ; Mueller BA
    SAGE Open Med; 2018; 6():2050312118773257. PubMed ID: 29780587
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Vancomycin clearance during continuous venovenous haemofiltration in critically ill patients.
    Boereboom FT; Ververs FF; Blankestijn PJ; Savelkoul TJ; van Dijk A
    Intensive Care Med; 1999 Oct; 25(10):1100-4. PubMed ID: 10551965
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Coagulase negative staphylococcal sepsis in neonates: do we need to adapt vancomycin dose or target?
    Padari H; Oselin K; Tasa T; Metsvaht T; Lõivukene K; Lutsar I
    BMC Pediatr; 2016 Dec; 16(1):206. PubMed ID: 27931193
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Population Pharmacokinetics and Dosing Optimization of Vancomycin in Pediatric Liver Transplant Recipients.
    Shoji K; Saito J; Nakagawa H; Funaki T; Fukuda A; Sakamoto S; Kasahara M; Momper JD; Capparelli EV; Miyairi I
    Microbiol Spectr; 2021 Oct; 9(2):e0046021. PubMed ID: 34612690
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The dosing and monitoring of vancomycin: what is the best way forward?
    Drennan PG; Begg EJ; Gardiner SJ; Kirkpatrick CMJ; Chambers ST
    Int J Antimicrob Agents; 2019 Apr; 53(4):401-407. PubMed ID: 30599240
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Pharmacokinetics, Pharmacodynamics, and Dose Optimization of Cefiderocol during Continuous Renal Replacement Therapy.
    Wenzler E; Butler D; Tan X; Katsube T; Wajima T
    Clin Pharmacokinet; 2022 Apr; 61(4):539-552. PubMed ID: 34792787
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.